Skip to main content
. Author manuscript; available in PMC: 2017 Jun 7.
Published in final edited form as: Stroke. 2016 Dec 27;48(2):379–387. doi: 10.1161/STROKEAHA.116.014735

Figure 3.

Figure 3

Time to breakeven point where long-term costs associated with stent retriever thrombectomy are exceeded by higher long term costs in the intravenous tissue-type plasminogen activator (IV tPA)–alone group.